Dimethyl Fumarate (DMF) Observational Study

The primary objective of the study is to determine the incidence, type, and pattern of
serious adverse events (SAEs), including but not limited to infections (including
opportunistic infections), hepatic events, malignancies, and renal events, and of adverse
events (AEs) leading to treatment discontinuation in patients with MS treated with dimethyl
fumarate (DMF). Secondary objectives of this study in this population are as follows: To
determine dimethyl fumarate (DMF) prescription and utilization patterns in routine clinical
practice in patients with multiple sclerosis (MS); To assess the effectiveness of dimethyl
fumarate (DMF) on multiple sclerosis (MS) disease activity and disability progression in
routine clinical practice as determined by the Expanded Disability Status Scale (EDSS) score
and multiple sclerosis (MS) relapse information; and To assess the effect of dimethyl
fumarate (DMF) on health-related quality of life, healthcare resource consumption, and work
productivity.